Main
>
ONCOLOGY (**)
>
Multiple Myeloma R/R ***
>
Treatment
>
FR. S. IsatuxiMAb+>2
FR. S. IsatuxiMAb+>2's subsections
(*) USA Approval Date: 2020. 03.02.
+Pomalidomide+Dexamethasone
>2 Prior Therapies Lenalidomide &
Binds CD38 Receptor
Company
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2020. 03.03.
PR Web-Site
TradeMark
FR. S. IsatuxiMAb+>2's products
This section has no products
(*) USA Approval Date: 2020. 03.02.
+Pomalidomide+Dexamethasone
>2 Prior Therapies Lenalidomide &
Binds CD38 Receptor
Company
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2020. 03.03.
PR Web-Site
TradeMark